A Colomer¹, N Erill¹, M Górriz^1,2, M Verdú², R Roman¹, R Ibáñez¹, C Cordon-Cardo¹ and X Puig^1,2.

^{1BIOPAT. Biopatologia Molecular, SL, Grup Assistència, Barcelona, Spain and 2 Histopat Laboratoris, Barcelona, Spain.}

Background: Topoisomerase II-alpha gene (TOP2A) aberrations have been recently pointed as predictive markers of anthracycline-based adjuvant chemotherapy in breast cancer. While coamplification of ERBB2 and TOP2A seems to define a subgroup of high-risk patients likely to benefit from anthracycline treatment, the significance of a patient having TOP2A deletions in […]

Montse Verdú ^1, Anna Colomer ², Ruth Román ², Nadina Erill ², Miquel Calvo ³, Abelardo Moreno ¹, Carlos Cordon-Cardó ⁴, Xavier Puig ^1,2.

HISTOPAT Laboratoris , Barcelona ^1. BIOPAT, Biopatologia Molecular, Barcelona ^2. Departament d’Estadística de la Universitat de Barcelona, Barcelona ³ y Division of Molecular Pathology,  Memorial Sloan-Kettering Cancer Center,  New York, USA ⁴.

The HER2/neu proto-oncogen is frequently amplified in breast cancer, and serves as a predictive biological determinant to guide trastuzumab therapy.  However, consensus has not been reached regarding […]

Verdú M^1, Colomer A^2, Román R^2, Erill N^2, Moreno A^1, Cordón-Cardo C^1,2, Puig X^1,2.

¹HISTOPAT Laboratoris & ²BIOPAT. Grup Assistència. Barcelona (Spain).

HER-2/neu is a critical marker in assessing the molecular profile of breast cancer, as it represents a target for therapeutic intervention. HER-2/neu gene amplification has been reported to be associated with treatment response. Immunohistochemistry (IHC) to detect HER-2/neu protein overexpression was initially recommended as the technique of choice to assign patients to Herceptin clinical treatment. However, different studies have shown […]

M. Guix Pericas ^1,2, C. Cordón Cardó ^1,2,3, M. A. Cañadas Bouzas ¹, A. Colomer Valero ²,  X. Puig Torrus ^1,2.

¹HISTOPAT S.A. Laboratoris. ²BIOPAT. Biopatologia molecular S.L. Grup Assistència. Barcelona. ³Memorial Sloan Kettering Cancer Center. Division of Molecular Pathology. Nueva York.

INTRODUCCIÓN

El carcinoma de mama es una de las neoplasias malignas más frecuentes y una de las primeras causas de muerte por cáncer. En la última década se ha incrementado notablemente su detección clínica y radiológica en estadios incipientes, y el […]